Analyst consensus rating
Lakefront Biotherapeutics Analyst Rating: Hold
Direct answer
Lakefront Biotherapeutics's consensus rating is Hold.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.49.
Forecast evidence checked November 13, 2026.
Get free Lakefront Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $33.93
- Average price target
- $30.49
- High price target
- $44.84
- Low price target
- $21.01
- Low target gap
- -38.1%
- Target upside
- -10.1%
- High target gap
- +32.2%
- Target range width
- 70.2%
- Consensus rating
- Hold
- Analysts
- 3
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Lakefront Biotherapeutics?
Lakefront Biotherapeutics has a verified Hold consensus. The same dataset has an average price target of $30.49.
How far are Lakefront Biotherapeutics's low and high targets from the recorded price?
The low target implies -38.1%, while the high target implies +32.2%.
How many analysts are included in Lakefront Biotherapeutics's consensus?
The verified consensus includes 3 analysts.
How is Lakefront Biotherapeutics's target upside or downside calculated?
The average target of $30.49 is divided by the recorded price of $33.93, then one is subtracted to produce -10.1%. This does not guarantee a future return.
When was Lakefront Biotherapeutics's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.